Table 1. Patient characteristics and in vitro treatment.
| Patient # | Source | Blast % | Bcr-Abl Status | Treatment/ Response |
In Vitro Treatment | In Vitro Cell Death/Protein/RNA Analysis | % CD34+ Q Cells |
|---|---|---|---|---|---|---|---|
| # 1 | PB | 73 | T315I | Failed imatinib, dasatinib, and nilotinib; progressed on PHA-739358. | N3a, ABT | P/Q | 8.7 |
| # 2 | PB | 75 | T315I, E255K | Failed imatinib and nilotinib. | N3a, ABT | P/Q | 1.7 |
| # 3 | PB | 25 | No Mutation | Failed imatinib, treated with nilotinib. | N3a, ABT, Nilotinib | P/Q WB, RT-PCR |
4.4 |
| # 4 | PB | 91 | T315I, E255K | Resistance to imatinib; treated with fludarabine, cytarabine, idarubicin, and cytarabine plus dasatinib. | N3a, ABT, Nilotinib | P/Q, Bulk,CD34+CD38− WB, PR-PCR, |
2.9 |
| # 5 | PB | 89 | T315I, E255V | Failed imatinib, dasatinib, nilotinib, and ponatinib. | N3a, ABT, Nilotinib | P/Q, Bulk,CD34+CD38− WB, RT-PCR, |
3 |
| # 6 | PB | 11 | No Mutation | Failed imatinib, dasatinib, nilotinib, and ponatinib; treat with decitabine and dasatinib and bosutinib. | N3a, ABT, Nilotinib | P/Q | 14.1 |
| # 7 | PB | 83 | H396R | Failed imatinib, dasatinib, nilotinib; treated with DCC-2036 and hydroxyurea. | N3a, ABT, Nilotinib | P/Q, Bulk,CD34+CD38− | 24 |
| # 8a | PB | 62 | T315I, E255V | Failed imatinib, dasatinib, ponatinib; treated with nilotinib; treat with decitabine and dasatinib. | N3a, ABT, Nilotinib | P/Q, WB, RT-PCR |
8 |
| #8b | BM | 86 | T315I | Failed imatinib, dasatinib, nilotinib and ponatinib; treated with chemotherapy and dual TKI, treated with fludarabine, cytarabine with ponatinib and dasatinib. | N3a, ABT, Nilotinib | Bulk, CD34+CD38 | |
| #9 | PB | 80 | No Mutation | Failed imatinib, dasatinib, | N3a, ABT, Nilotinib | Bulk |
N3a, nutlin3a; ABT, ABT-737; WB, west blot; P, proliferating; Q, quiescent.